eyeforpharma Barcelona Conference, Expo & Awards 2019

eyeforpharma12 - 14 March 2019, Barcelona, Spain.
It's 2019, and it's time for something new. Attendance is ahead of expectations, eyeforpharma Barcelona is on track for over 1300 pharma decision makers from Sales, Marketing, Patient Engagement, Patient Advocacy, Medical Affairs, Digital, Market Access and RWE functions to fuse with health innovators, payers, patients, start-ups and cutting-edge tech.

On current projections, tickets will sell out this year. Ensure you have a place reserved at the only meeting where executives forge a new future for the pharma industry.

Medicine is just the beginning

Medicines are essential, yet they're rarely the entire solution. As we shift focus to outcomes, we need to be prepared to deliver value in whatever form is best for patients. The keynote sessions at eyeforpharma Barcelona will cover:
  • Value, driven.
    Change your mindset to reach beyond the incremental - and find bold solutions for real patients. Only then will outcomes be transformed.
  • Authenticity rules.
    Use greater patient insights to build trust with customers and fight for the best patient journey. Make education and credibility your mantra!
  • Tech is fundamental.
    See how digital ML & AI are delivering the data that rewrites your business plan, sets new standards and makes the connected future a reality.
  • Welcome new customers.
    Exceed elevated expectations by aligning to consumerisation - and setting new goals in wellbeing, prevention and regeneration.

New for 2019

The Innovation Stage

A showcase of bleeding-edge, industry-transforming science and new ideas which will open your eyes to the coming disruptions.

Real-World Evidence Europe Summit

For 2019 we've added our industry-leading Real-World Evidence Summit to the event to show the role RWE will play in the shift to value

The im-patient conference

Patient-focused conferences are usually designed by pharma. Until now! This time, patients have created the agenda and line-up.

Market Access Europe Summit

Market Access is vital for pharma's commercial success - that's why for 2019 it has been added as a key topic.

This is the world's biggest commercial pharma meeting and your opportunity to join 1300+ pharma leaders focused Sales, Marketing, Patient Engagement, Market Access, Medical Affairs and Real-World Evidence

World Pharma News readers can benefit from an exclusive discount, just use the code WPN300 to save €300 when you register here

For further information, please visit:
http://www.eyeforpharma.com/barcelona/

About eyeforpharma

Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the centre.

Most Popular Now

Compound that kills drug-resistant fungi is isolat…

Antimicrobial and antifungal resistance, which describe the ability of bacteria and other pathogens to resist the effects of drugs to which they were once sensitive, is a...

Novartis receives FDA approval for Mayzent® (sipon…

Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple scl...

First bacterial genome created entirely with a com…

All the genome sequences of organisms known throughout the world are stored in a database belonging to the National Center for Biotechnology Information in the United Sta...

Immune cells fighting blood cancer visualized for …

When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) re...

Liver, colon cancer cells thwarted by compounds de…

The plant that adds flavor, color and bitterness to beer also produces a primary compound that thwarts cancer cells, and two important derivatives of the compound do as w...

Clinical trial finds therapy to be well-tolerated …

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated...

FDA approves treatment for patients with a type of…

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called no...

Selumetinib granted US Breakthrough Therapy Design…

AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) ha...

Boehringer Ingelheim announces FDA and EMA regulat…

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and E...

Novartis adds clinical and preclinical anti-inflam…

Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC fo...

Novartis continues transformation into a leading m…

Novartis today completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution to holders of Novartis shares and ADRs (American Depo...

Forxiga approved in Japan for type-1 diabetes

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T...